Regulus Therapeutics (RGLS) Tops Q1 EPS by 10c

Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.15), $0.10 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Bank of America (BAC) Tops Q2 EPS by 9c, Beats on Revenue
• Bank of New York Mellon (BNY) call put ratio 1 call to 2 put into quarter results
• Canaccord Reiterates Buy Rating on Hillman Solutions Corp. (HLMN)